Literature DB >> 7298924

Inhibition of histamine-induced pruritus by topical tricyclic antidepressants.

J E Bernstein, D H Whitney, K Soltani.   

Abstract

Frequent antihistaminic side effects noted during treatment of depression by tricyclic drugs, as well as the high affinity of tricyclic antidepressants for H1 receptors in mouse neuroblastoma cells, suggest possible useful antihistaminic properties. We investigated the antipruritic activity of topically applied 5% solutions of doxepin hydrochloride (Adapin; Sinequan) and amitriptyline hydrochloride (Elavil) and compared such activity to that of a 5% solution of diphenhydramine and vehicle alone. Test solutions were applied to 25-cm2 areas on the flexor forearms of forty subjects, and the development of itch to single drops of eight dilutions of histamine phosphate instilled in each area was reported over a 3-minute period. The lowest concentration of histamine able to elicit unequivocal itching in each treated area was the histamine itch threshold (HIT). Doxepin, amitriptyline, and diphenhydramine all produced significantly higher mean and median HITs (p less than 0.01 than did vehicle control. Sixty-eight percent of subjects had a HIT greater than or equal to 2 x 10(-4) mg/ml in doxepin-treated areas versus 58% for amitriptyline, 53% for diphenhydramine, and 25% for vehicle. Our data suggest that tricyclic antidepressants are effective topical antipruritic agents.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7298924     DOI: 10.1016/s0190-9622(81)70120-8

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  4 in total

Review 1.  [Antidepressant drugs : a reasonable therapy for pruritus?].

Authors:  U Raap; A Kapp; U Darsow
Journal:  Hautarzt       Date:  2012-07       Impact factor: 0.751

2.  Protective effects of doxepin cream on radiation dermatitis in breast cancer: A single arm double-blind randomized clinical trial.

Authors:  Laleh Shariati; Alireza Amouheidari; Hajar Naji Esfahani; Alireza Abed; Shaghayegh Haghjooy Javanmard; Ismail Laher; Ahmad Ghasemi; Golnaz Vaseghi
Journal:  Br J Clin Pharmacol       Date:  2020-02-25       Impact factor: 4.335

Review 3.  Bottlenecks in the development of topical analgesics: molecule, formulation, dose-finding, and phase III design.

Authors:  Jan M Keppel Hesselink; David J Kopsky; Stephen M Stahl
Journal:  J Pain Res       Date:  2017-03-20       Impact factor: 3.133

Review 4.  Topical Treatments and Their Molecular/Cellular Mechanisms in Patients with Peripheral Neuropathic Pain-Narrative Review.

Authors:  Magdalena Kocot-Kępska; Renata Zajączkowska; Joanna Mika; David J Kopsky; Jerzy Wordliczek; Jan Dobrogowski; Anna Przeklasa-Muszyńska
Journal:  Pharmaceutics       Date:  2021-03-26       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.